Highlights OptiNose, Inc.

Equities

OPTN

US68404V1008

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.26 ^USD	-2.33%		+3.28%	-2.33%

May. 14	Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 14	Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M	May. 14	MT
OptiNose, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024	May. 09	CI
OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	Apr. 25	CI
OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025	Apr. 25	CI
OptiNose Says US FDA Approves Xhance to Treat Chronic Rhinosinusitis	Mar. 15	MT
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older	Mar. 15	CI
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement	Mar. 14	CI
Earnings Flash (OPTN) OPTINOSE Posts Q4 Revenue $19.9M	Mar. 07	MT
OptiNose, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024	Mar. 07	CI
OptiNose, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology	Jan. 18	CI
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE	Dec. 06	CI
Earnings Flash (OPTN) OPTINOSE Posts Q3 Revenue $19.8M	Nov. 09	MT
OptiNose, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
OptiNose, Inc. Revises Revenue Guidance for the Full Year of 2023	Nov. 09	CI
OptiNose Raises Full-Year 2023 Xhance Net Revenue Outlook	23-08-10	MT
OptiNose, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (OPTN) OPTINOSE Reports Q2 Revenue $19.5M	23-08-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights OptiNose, Inc.

Equities

OPTN

US68404V1008

Highlights

Filters